標(biāo)題: Titlebook: High Performance Computing in Science and Engineering ‘11; Transactions of the Wolfgang E. Nagel,Dietmar B. Kr?ner,Michael M. Res Conferen [打印本頁(yè)] 作者: Inveigle 時(shí)間: 2025-3-21 18:51
書(shū)目名稱High Performance Computing in Science and Engineering ‘11影響因子(影響力)
書(shū)目名稱High Performance Computing in Science and Engineering ‘11影響因子(影響力)學(xué)科排名
書(shū)目名稱High Performance Computing in Science and Engineering ‘11網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱High Performance Computing in Science and Engineering ‘11網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱High Performance Computing in Science and Engineering ‘11被引頻次
書(shū)目名稱High Performance Computing in Science and Engineering ‘11被引頻次學(xué)科排名
書(shū)目名稱High Performance Computing in Science and Engineering ‘11年度引用
書(shū)目名稱High Performance Computing in Science and Engineering ‘11年度引用學(xué)科排名
書(shū)目名稱High Performance Computing in Science and Engineering ‘11讀者反饋
書(shū)目名稱High Performance Computing in Science and Engineering ‘11讀者反饋學(xué)科排名
作者: Medicare 時(shí)間: 2025-3-21 20:47
978-3-662-50844-2Springer-Verlag Berlin Heidelberg 2012作者: leniency 時(shí)間: 2025-3-22 03:41 作者: ADORN 時(shí)間: 2025-3-22 07:44 作者: Canary 時(shí)間: 2025-3-22 11:56 作者: ARCHE 時(shí)間: 2025-3-22 14:06
Wolfgang E. Nagel,Dietmar B. Kr?ner,Michael M. ResIncludes supplementary material: 作者: 比喻好 時(shí)間: 2025-3-22 20:36 作者: Crater 時(shí)間: 2025-3-22 22:22 作者: Presbyopia 時(shí)間: 2025-3-23 01:47
tinuous mapping from the L-fuzzy unit interval to an L-fuzzy topological space. To obtain this result we describe the product of paths as the universal arrow of a pushout. On the other hand we show (using a Boolean valued model) how to obtain a reasonable definition of the product of fuzzy paths.作者: accomplishment 時(shí)間: 2025-3-23 06:05 作者: 易達(dá)到 時(shí)間: 2025-3-23 11:55 作者: 防止 時(shí)間: 2025-3-23 15:49 作者: Thyroid-Gland 時(shí)間: 2025-3-23 18:54 作者: Gudgeon 時(shí)間: 2025-3-24 01:21
Philipp Gerhold,Karl Jansen,Jim Kallarackalc and malolactic fermentations. Despite the traditional aspect of cider, cidermaking industry researches improvement of the process to control the two fermentations and the production of flavouring components. During the two last decades interest was given to the application of the cell immobilisati作者: GUISE 時(shí)間: 2025-3-24 04:00 作者: 泄露 時(shí)間: 2025-3-24 06:33
ons.Includes supplementary material: .Cell immobilisation biotechnology is a multidisciplinary area, shown to have an important impact on many scientific subdisciplines – including biomedicine, pharmacology, cosmetology, food and agricultural sciences, beverage production, industrial waste treatment作者: 臥虎藏龍 時(shí)間: 2025-3-24 11:47
Johannes Roth,Johannes Karlin,Christian Ulrich,Hans-Rainer Trebin,Steffen Sonntagis in the form of coated activated charcoal for haemoperfusion. Implantation of encapsulated cells are being studied for the treatment of diabetes, liver failure and the use of encapsulated genetically engineered cells for gene therapy. Blood substitutes based on modified haemoglobin are already in 作者: collateral 時(shí)間: 2025-3-24 15:48 作者: 削減 時(shí)間: 2025-3-24 22:00 作者: 長(zhǎng)處 時(shí)間: 2025-3-25 02:57 作者: Flatus 時(shí)間: 2025-3-25 03:35
Peter Schmitteckertis in the form of coated activated charcoal for haemoperfusion. Implantation of encapsulated cells are being studied for the treatment of diabetes, liver failure and the use of encapsulated genetically engineered cells for gene therapy. Blood substitutes based on modified haemoglobin are already in 作者: 態(tài)學(xué) 時(shí)間: 2025-3-25 11:02
A. Moreno,A. Muramatsu,S. Manmanais in the form of coated activated charcoal for haemoperfusion. Implantation of encapsulated cells are being studied for the treatment of diabetes, liver failure and the use of encapsulated genetically engineered cells for gene therapy. Blood substitutes based on modified haemoglobin are already in 作者: PHONE 時(shí)間: 2025-3-25 13:10
is in the form of coated activated charcoal for haemoperfusion. Implantation of encapsulated cells are being studied for the treatment of diabetes, liver failure and the use of encapsulated genetically engineered cells for gene therapy. Blood substitutes based on modified haemoglobin are already in 作者: JUST 時(shí)間: 2025-3-25 18:04
J.-H. Franke,N. N. Nair,L. Chi,H. Fuchsis in the form of coated activated charcoal for haemoperfusion. Implantation of encapsulated cells are being studied for the treatment of diabetes, liver failure and the use of encapsulated genetically engineered cells for gene therapy. Blood substitutes based on modified haemoglobin are already in 作者: Gudgeon 時(shí)間: 2025-3-26 00:01 作者: 休息 時(shí)間: 2025-3-26 01:03 作者: AGATE 時(shí)間: 2025-3-26 04:44
The Influence of the Mass Ratio on Particle Acceleration by the Filamentation Instabilityons of counterstreaming plasma. Under these conditions the plasma is susceptible to filamentation instabilities. Analytical analysis of this environment is highly non-trivial, which leads to the extensive use of computer simulations to study these conditions and the connection to the energetic photo作者: Aboveboard 時(shí)間: 2025-3-26 09:39
The SuperN-Project: Neutrino Hydrodynamics Simulations of Core-Collapse Supernovaeations and the algorithm for its solution that are employed in our code .. We also discuss the parallelisation of ., give scaling results on different architectures, and report on our ongoing efforts to increase the computational efficiency of the code. Furthermore, we outline some of the recent res作者: Notify 時(shí)間: 2025-3-26 14:00
Simulation of Pre-planetesimal Collisions with Smoothed Particle Hydrodynamicssimals is not well constrained. In this regime of pre-planetesimals, collisional growth is endangered by disruptive collisions or mutual rebound and compaction. Both obstacles are addressed in our work. Since laboratory studies of pre-planetesimal collisions are infeasible beyond centimetre-size, we作者: Substance-Abuse 時(shí)間: 2025-3-26 17:29
QCD Critical Surfaces at Real and Imaginary , the known hadronic phase to a plasma phase, where quarks and gluons are no longer confined. For small and large quark masses, these are first order chiral and deconfinement transitions, respectively, whereas for intermediate masses they are only analytic crossovers, separated by critical surfaces. 作者: FELON 時(shí)間: 2025-3-26 22:54 作者: 旁觀者 時(shí)間: 2025-3-27 03:51 作者: 一再煩擾 時(shí)間: 2025-3-27 07:25 作者: 本能 時(shí)間: 2025-3-27 09:31 作者: LEER 時(shí)間: 2025-3-27 15:33 作者: bioavailability 時(shí)間: 2025-3-27 19:20 作者: transient-pain 時(shí)間: 2025-3-28 00:22
Obtaining the Full Counting Statistics of Correlated Nanostructures from Time Dependent Simulationsity matrix renormalization group method to study transport properties of quantum devices attached to metallic leads..To this end we have developed two complementary approaches to obtain conductance of a structure coupled to left and right leads. First we use the Kubo approach to obtain linear conduc作者: 設(shè)施 時(shí)間: 2025-3-28 05:34
Phase Diagram of the 1D t-J Model separating the repulsive from the attractive Luttinger-liquid (LL) phase, and also the boundaries of the spin-gap region and phase-separation, are determined on the basis of correlation functions and energy gaps. In particular, we shed light on a contradiction between variational and renormalizatio作者: 遣返回國(guó) 時(shí)間: 2025-3-28 06:46 作者: 平躺 時(shí)間: 2025-3-28 10:58 作者: Grating 時(shí)間: 2025-3-28 18:13 作者: DEBT 時(shí)間: 2025-3-28 19:48 作者: Autobiography 時(shí)間: 2025-3-29 01:19
QCD Critical Surfaces at Real and Imaginary , r three degenerate flavours at zero and finite density on . .=6 lattices, corresponding to a lattice spacing of .～0.2 fm. Furthermore, we compute the phase structure at imaginary chemical potential ./.=./3, finding tricritical lines which bound the continuation of the chiral as well as the deconfine作者: 積云 時(shí)間: 2025-3-29 04:21 作者: 埋伏 時(shí)間: 2025-3-29 08:45 作者: 音的強(qiáng)弱 時(shí)間: 2025-3-29 14:48 作者: 弄臟 時(shí)間: 2025-3-29 18:02 作者: 令人發(fā)膩 時(shí)間: 2025-3-29 20:44 作者: epinephrine 時(shí)間: 2025-3-30 03:26 作者: Ingredient 時(shí)間: 2025-3-30 04:19 作者: BUCK 時(shí)間: 2025-3-30 10:41
mobilisation while the present volume, FOBI 8B, Applications of Cell Immobilisation Biotechnology, deals with diverse applications of this technology. ..978-90-481-6820-0978-1-4020-3363-6Series ISSN 1569-268X 作者: Interim 時(shí)間: 2025-3-30 14:56 作者: 沉著 時(shí)間: 2025-3-30 20:20
Stefan Maintz,Bernhard Eck,Richard Dronskowskimobilisation while the present volume, FOBI 8B, Applications of Cell Immobilisation Biotechnology, deals with diverse applications of this technology. ..978-90-481-6820-0978-1-4020-3363-6Series ISSN 1569-268X 作者: Impugn 時(shí)間: 2025-3-31 00:24
Conference proceedings 2012nce Computing Center Stuttgart (HLRS) for the year 2011. The reports cover all fields of computational science and engineering, ranging from CFD to computational physics and chemistry, to computer science, with a special emphasis on industrially relevant applications. Presenting results for both vec作者: 光明正大 時(shí)間: 2025-3-31 01:15 作者: NEEDY 時(shí)間: 2025-3-31 08:00
Johannes Roth,Johannes Karlin,Christian Ulrich,Hans-Rainer Trebin,Steffen Sonntage being developed for clinical trial in hereditary enzyme deficiency diseases and other diseases. Artificial cell is also being investigated for drug delivery and for other uses in biotechnology, chemical engineering and medicine.作者: harangue 時(shí)間: 2025-3-31 12:15
Gabriel Bester,Peng Hane being developed for clinical trial in hereditary enzyme deficiency diseases and other diseases. Artificial cell is also being investigated for drug delivery and for other uses in biotechnology, chemical engineering and medicine.作者: 農(nóng)學(xué) 時(shí)間: 2025-3-31 13:55 作者: tinnitus 時(shí)間: 2025-3-31 18:16
Peter Schmitteckerte being developed for clinical trial in hereditary enzyme deficiency diseases and other diseases. Artificial cell is also being investigated for drug delivery and for other uses in biotechnology, chemical engineering and medicine.作者: APNEA 時(shí)間: 2025-3-31 23:35
A. Moreno,A. Muramatsu,S. Manmanae being developed for clinical trial in hereditary enzyme deficiency diseases and other diseases. Artificial cell is also being investigated for drug delivery and for other uses in biotechnology, chemical engineering and medicine.
